The question of co-existent bacterial bronchitis in an acute exacerbation of asthma has not been resolved. Many textbooks advise antibiotic treatment on the assumption that aggravated asthma is always connected with a purulent bronchitis. Graham et al, 9 in a placebo-controlled trial, showed that recovery from an attack of asthma was not enhanced in the group who received amoxycillin compared to the control group. The authors conclude that antibiotics should not be given routinely to patients with acute exacerbations of asthma. The findings from a study of transtracheal aspiration in asthmatic patients 10 do not support the empiric use of antibiotics in the management of unexplained asthmatic relapse. In any case, the effect of antibiotic treatment in acute asthma would not be evident until several hours after initiation of the treatment. Hudgel et al u found that viral but not bacterial respiratory tract infections were significantly increased during wheezing exacerbations in adult asthmatic patients. In some asthmatic patients, the respiratory tract was chronically colonized with "pathogenic" bacteria without increased frequency of asthmatic exacerbations. It is, however, possible that spasmogenic substances are released during a bacterial infection, thus exacerbating the asthmatic symptoms in some cases. Clinically some patients certainly seem to benefit from antibiotic treatment during the recovery phase after an acute attack of asthma. This treatment should be critical, under specific circumstances, and not routine. One should try to evaluate specific diagnostic criteria, which in the case of sinusitis would be based on radiologic evidence and the findings of a sinus puncture. Sputum production is one of the main symptoms of asthma and should not as such be taken as a sign of bronchial infection. Evaluation of sputum appearance is best done when the esinophilia, a common cause of purulent looking sputum, has been eradicated with corticosteroids. Bacterial culture of sinus fluid gives reliable results, but the microbiologic findings of a culture of normally expectorated sputum may not be clinically relevant. Our policy when treating acute asthma has been to give an antibiotic if the bacterial infection is obvious, ie, radiologic evidence of a fluid level in the nasal sinuses, or pneumonia. In doubtful cases we wait. If on the third or fourth day of intensive antiasthmatic treatment (including corticosteroids) the patient has purulent-looking expectorant, we start antibiotic therapy.
Bacterial infections of nasal sinuses and bronchi are probably secondary to mucosal edema, hypersecretion, bronchospasm and mucociliary dysfunction. There is no evidence that they are the primary cause of an exacerbation of asthma (Fig 1) . It is possible that some bacterial infections will limit themselves, if the pathologic state of the mucosa is reversed and its normal function restored 12 by the antiasthmatic medication.
The question of specific vaccination has been raised recendy. Goldstein, 13 in a discussion, objects to manufacturers claiming that asthmatic patients should be included in the risk group who should receive pneumococcal vaccine. As Goldstein points out, asthmatic patients are not at risk of developing pneumococcal pneumonia. The reply from the manufacturer represented by Fiumara 1 ' 1 is not convincing.
The available evidence suggests that bacterial infections in asthma and allergic rhinitis may not always need treatment, and if they are treated, this may not be sufficient to reverse the symptoms of asthma (Fig 1) . Prophylactic treatment of There is some anecdotal evidence of bacterial infection having a temporarily beneficial effect in asthma, at least if in connection with fever. 15 Artificially induced fever was once used in the treatment of asthma. King William of Orange, who is said to have had asthma, was wounded in his shoulder in one of his battles against the Catholics. The wound, slow in healing, was purulent for months. During the time when the infection was obvious, the king was free from asthmatic symptoms.
VIRAL INFECTIONS
Mechanisms of bronchial obstruction caused by viral infections have been studied. 1618 Normal subjects demonstrate exaggerated reactions-obstruction and cough-to histamine, methacholine, carbacholine and citric acid up to six weeks after a viral upper respiratory tract infection. This reaction can be prevented and reversed by administration of isoprenaline and atropine. Empey and colleagues 16 conclude that viral infections cause damage in the epithelium which exposes and therefore sensitizes the vagal receptors. 16 Viral infections may also reduce beta-adrenergic responsiveness, thus enhancing broncbial hyperactivity. 1920 In some individuals, the beginning of asthma as a clinical disease seems to be attributable to a respiratory viral infection. It is possible that these patients, if tested, would have been hyperreactive prior to the infection. Carlsen and Orstavik 26 showed that in children, especially rhinovirus and respiratory syncytial virus provoke attacks of asthma.
Infections are believed to play an important role especially in intrinsic asthma, but according to Roldaan and MasuraP the development of viral exacerbations in asthmatic patients is not determined by whether the patient is allergic or not. It seems probable that one of the facts which determines whether an asthmatic will have an exacerbation of the disease during a viral infection is not atopy, but the severity of the disease. The clinician will see relatively more exacerbations of asthma during viral infections in the patient with intrinsic asthma, because clinically, intrinsic asthma is often more severe than atopic asthma.
Although the evidence of benefit is not conclusive, it has been recommended that all patients with severe asthma, except for those with egg hypersensitivity, should be immunized annually against influenza. 27 On the other hand, several reports have suggested that asthmatic patients may experience an exacerbation of bronchial symptoms following immunization with killed or live influenza vaccine.
To investigate the possible adverse and beneficial effects of such vaccination, we conducted a multicenter placebo controlled study. 32 Patients with moderately severe chronic asthma who were known to have exacerbations of their disease in connection with upper respiratory viral infections were followed closely during the week after vaccination and thereafter at regular intervals over the following six months. There was no significant decrease in the mean peak flow rates during the first post-vaccination week in the 321 immunized patients as compared to the placebo-group. Atopic status, ASA intolerance, history of exacerbations of asthma in connection to respiratory infections, the use of oral corticosteriods or duration of the asthma did not influence the asthmatic symptoms after vaccination. The antibody response to vaccination was normal. Unfortunately, the protective effect of the vaccination could not be estimated since there was no epidemic of influenza during the following year. However, this has been shown in other patient groups. 33 There is no reason to believe that asthmatic patients could not be protected from viral infection in this manner. We concluded that there are no risks connected to immunization with inactivated vaccines in asthmatic patients. The fact that all our patients were placed on optimal anti-asthmatic treatment before the trial may have contributed to (he favorable result.
The effect of recurrent viral infection on the prognosis of asthma is hard to evaluate. There are no investigations on long-term effects of recurrent infections or on the beneficial value of preventing them.
FUNGAL INFECTIONS
The intrabronchial growth of Aspergillus fumigatus may cause exacerbations of asthma. The mechanism of this exacerbation is not direct infection, but its immunologic consequences. This is seen in bronchopulmonary aspergillosis (APBA), in which the antibody response to the fungus adhering to the bronchi causes worsening of the asthma. The management of this condition consists of vigorous treatment of the asthma including corticosteroids. Antifungal treatment is not beneficial in APBA. 34 Probably corticosteroids lessen the antigen-antibody reaction and restore the normal defence mechanisms of bronchial mucosa. As a result the mycelium is expectorated. In APBA, prevention of acute exacerbations is essential to avoid permanent damage of the bronchial tree.
Colonization of the pharynx with Candida albicans in patients taking steroid aerosols occurs frequently, but has not been shown to have aggravating effects on the asthma.
